USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, May 9, 2024 /PRNewswire/ — USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer Moon Shot” designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

In the case of pelareorep, an intravenously delivered immunotherapy agent developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), the case is getting stronger for it to one day become a treatment for multiple cancers, including most prominently pancreatic cancer. Near the end of 2022, the FDA granted pelareorep a Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) after it demonstrated some optimistic results. Now Oncolytics is continuing to move its flagship asset forward, having recently received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRONOX +/- Tecentriq® (from Roche) in pancreatic cancer in a new cohort for its ongoing GOBLET study, following German regulatory and ethics approvals.

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.

“Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC,” said Dr. Matt Coffey, President and CEO of Oncolytics. “We believe that working with PanCAN will help to further enrich Oncolytics’ clinical relationships with the pancreatic cancer community. We are also grateful for PanCAN’s Therapeutic Accelerator Award, which is enabling the evaluation of this combination therapy.”

Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep’s potential in addressing pancreatic cancer. So far, Oncolytics has already reported data for pelareorep in combination with gemcitabine and nab-paclitaxel. According to the Oncolytics team, if the mFOLFIRINOX combination shows a compelling efficacy signal, this therapeutic approach could also be advanced to a registration-enabling study, providing two opportunities for pelareorep-based treatment to benefit pancreatic cancer patients. In addition, translational research studies planned for this cohort will help to further elucidate pelareorep’s mechanism of action, including its ability to shape the tumor microenvironment (TME).

“Oncolytics has taken a very strategic approach to the development of pelareorep in pancreatic cancer by focusing its clinical studies on combinations with the most widely used treatment regimens,” said Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial. “My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging anal cancer data reported last year, makes me enthusiastic to initiate enrollment in the mFOLFIRINOX cohort.”

Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs) in the blood, an effect that was observed in earlier pancreatic cancer studies. According to the company, they will be initiating enrollment into the mFOLFIRINOX/pelareorep study cohort in Q2 2024.

In the case of Candel Therapeutics, Inc. (NASDAQ: CADL), another potential treatment for pancreatic cancer was given a nod by the FDA in the form of an Orphan Drug Designation given to Candel’s most advanced multimodal biological candidate, CAN-2409. The news of the designation came weeks after Candel reported updated overall survival data from its ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable PDAC.

“We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. “We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this program, as we seek to reshape the treatment paradigm in pancreatic cancer.”

Pharma giant AstraZeneca PLC (NASDAQ: AZN) recently saw its revenue spike in Q1 2024, bolstered by sales of its cancer medicines, according to Bloomberg. Over the last few weeks, AstraZeneca has been making more progress across the oncology scene, including the release of topline findings from its Phase III DESTINY-Breast06 study, showing significant progression-free survival benefits in certain patients with metastatic breast cancer with its antibody-drug conjugate Enerhertu with partners Daiichi Sankyo.

As well, AstraZeneca also reported results for its CALQUENCE combination regimen, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival improvement in 1^st-line mantle cell lymphoma from its ECHO Phase III trial.

“These impactful results in mantle cell lymphoma show that bringing CALQUENCE to the first-line setting significantly delays disease progression and, for the first time, shows potential to extend survival,” said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. “The improvement in progression-free survival together with the differentiated safety profile of CALQUENCE are both important as we strive to transform outcomes earlier in the course of disease treatment.”

In combination with its Enhanze drug-delivery technology, Halozyme Therapeutics, Inc. (NASDAQ: HALO) was recently linked to the acceptance of an approval-seeking FDA application involving a subcutaneous formulation of Bristol-Myers Squibb’s blockbuster cancer drug Opdivo. As per the announcement, the application covers Opdivo co-formulated with Halozyme’s Enhanze drug-delivery technology across all previously approved adult, solid-tumor Opdivo indications as monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy or in combination with chemotherapy or cabozantinib.

Back in January, Halozyme also saw its other co-collaborator, Roche, receive European Commission approval of Tecentriq® SC with Enhanze, representing the EU’s first subcutaneous PD-(L)1 cancer immunotherapy for multiple cancer types.

“As the first subcutaneous PD-(L)1 cancer immunotherapy in Europe, Tecentriq SC can provide a new treatment option that can enhance the treatment experience for patients and caregivers while freeing up resources in constrained healthcare systems,” said Dr. Helen Torley, President and CEO of Halozyme.

Back in February, Janux Therapeutics, Inc. (NASDAQ: JANX) announced encouraging safety and efficacy data in ongoing dose escalation trials for PSMAxCD3-TRACTr JANX007 in metastatic castration-resistant prostate cancer (mCRPC) and EGFRxCD3-TRACTr JANX008 in late-stage solid tumors.

“The clinical data provide compelling proof-of-concept for the TRACTr platform in a setting where many other approaches have failed due to material safety issues or lack of efficacy,” said David Campbell, Ph.D., President and CEO, Janux Therapeutics. “Our TRACTr platform provides an entry point to multiple, large solid tumor indications that are intractable with conventional TCE approaches. We look forward to continuing to advance these clinical trials and expanding to additional TCE targets, as we look to fulfill our mission to meaningfully address the unmet medical needs for cancer patients, especially those with late-stage disease.”

The market’s immediate reaction was quite positive upon these results, but by mid-April Janux began working with an adviser after drawing interest in a potential takeover. According to Bloomberg, Janux is likely to draw interest from bigger drugmakers who are looking to acquire new medicines to replenish their portfolios or expand into cancer treatments. Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Article Source: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

USA NEWS GROUP
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/biotech-innovations-surge-as-global-cancer-diagnosis-rates-continue-to-climb-302141329.html

Hylobiz’s B2B lending platform tech built upon Hedera’s decentralized network focused on enabling streamlined digital access to low-cost financing for SMBs globally. 

HYDERABAD, India, May 9, 2024 /PRNewswire/ — The Hashgraph Association (THA), the Swiss-based organization at the forefront of global digital enablement, has partnered with Hylobiz, a Vayana group company, for the launch of decentralized debt-based financial products built on the Hedera DLT network. Leveraging Hedera’s decentralized, open-source public ledger, Hylobiz’s software as a service (SaaS) B2B lending platform enables easier access to affordable financing for small and medium-sized businesses (SMBs) globally.

With 65 million firms, or 40% of formal micro, small, and medium enterprises in developing countries, facing unmet financing needs of $5.2 trillion every year, Hylobiz is addressing this financing gap through a blockchain-powered solution. The collaboration with THA will expand the on-chain availability and adoption of debt-based financial products in traditional and capital markets, thereby giving the real-world asset (RWA) segment access to a larger pool of liquidity.

Using the Hedera decentralized public network, Hylobiz is providing an infrastructure for SMBs to help reduce the overall cost of servicing loans, facilitate easier movement of capital from a surplus location in the world to a deficit one, and use features of programmable money to bring efficiencies. The offering includes access to Vayana Debt Platform (VDP), a securities & loan tokenization module available off-the-shelf for lending businesses to handle digital currency-based transactions and deploy on Hedera immediately. 

Kamal Youssefi, President of The Hashgraph Association, stated, “We share the same vision of Hylobiz and Vayana in creating an ecosystem where digital finance is embedded in a transaction invisibly, securely, and transparently. We are proud to be partnering with the Vayana group and believe that the Hedera DLT network is essential for the growth of SMBs in emerging markets, evening out the playing field and allowing them to compete on equal footing with the big global industry players.”

Manish Gadia, Head Emerging Tech Platforms (ETP) at Vayana Group, commented, “Hylobiz’s partnership with THA fits within Vayana’s mandate to serve the B2B debt segment digitally with a special focus on SMBs, ensuring the lowest affordable landing cost. Vayana Group has proven expertise in Web2 and through partnerships such as this we are extending our capabilities of creating world-class financing infrastructure in Web3 as well. Usage of blockchain and smart contracts will help usher in a new age of finance and by democratizing access to this new realm, the Vayana ecosystem is ensuring that SMBs aren’t left behind.”

About Hylobiz – A Vayana Group Company

Hylobiz – A Vayana Group Company builds solutions targeted primarily to small businesses and financial services. Hylobiz’s digital-first solution is a unified FinTech platform that solves cash flow management in a way that helps businesses to manage their accounts receivables and accounts payables with greater ease.

To Facilitate growth of deserving MSMEs/ Micro Entrepreneurs, alongside other incidental areas where the working capital credit gap remains globally, Vayana Debt Platform (“VDP”) is built as a comprehensive blockchain-based loan operating system for digital currencies/deposit tokens/CBDC/Fiat. It enables regulated/alternate lenders and other credit investors to lend to businesses on the Blockchain, harnessing the power of smart contracts to fully digitize their lending operations.

Parent company Vayana is India’s Largest Trade Credit Infrastructure, specializing in supply chain finance & other B2B trade credit solutions. Vayana’s mission is to democratize the access of timely and affordable trade credit to the smallest entity in the supply chain. Headquartered in India, Vayana has partnered with 20+ banks, serving 3000 supply chains. Vayana offers a range of solutions via its trade finance infrastructure to help enterprises optimize every day B2B Trade. Visit www.vayana.com

About The Hashgraph Association

The Hashgraph Association is at the forefront of the digital enablement and empowerment of organizations through the broad adoption of Hedera-powered enterprise-grade solutions and decentralized applications, including funding training, innovation, and venture building programs globally. As a non-profit organization headquartered in Switzerland, The Hashgraph Association supports and funds innovation, research, and development that enables economic inclusion and a digital future for all, with a positive environmental, social, and governance (ESG) impact. For further information about The Hashgraph Association, visit www.hashgraph-association.com.

View original content:https://www.prnewswire.co.uk/news-releases/the-hashgraph-association-and-hylobiz—a-vayana-subsidiary—launch-debt-based-financial-products-on-hedera-dlt-network-302141563.html

USA News Group Commentary Issued on behalf of Bee Vectoring Technologies International Inc.

VANCOUVER, BC, May 9, 2024 /PRNewswire/ — USA News Group – In order to help farmers advance conservation and climate-smart agriculture, the USDA recently made $1.5 billion available as part of US President Biden’s Investing in America Agenda. The newly-available capital is part of several climate-smart agriculture investments the USDA has made since the beginning of the current Administration’s reign, which have been made through the Inflation Reduction Act, and the Partnerships for Climate-Smart Commodities program, which have been estimated to support over 180,000 farms and over 225 million acres in the next 5 years. According to analysts at Straits Research the Smart Agriculture Market is projected to reach US$36.24 billion by 2030, growing at a CAGR of 10.8%, while Markets and Markets predicts the Precision Farming Market to grow to US$21.9 billion by 2031, growing at a CAGR of 10.7%. As farmers and the agriculture industry works to produce environmentally friendly food that meets these goals, several agritech companies are working behind the scenes to help, including Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF), Nutrien Ltd. (NYSE: NTR) (TSX: NTR), The Mosaic Company (NYSE: MOS), CF Industries Holdings, Inc. (NYSE: CF), and Bunge Global SA (NYSE: BG).

With its innovative system that utilizes commercially reared bees to deliver biological pesticide alternatives directly to crops, Bee Vectoring Technologies International Inc. (BVT) (CSE: BEE) (OTCQB: BEVVF) is poised to disrupt the $250 billion crop protection and fertilizer market. Biological agricultural products, often referred to as biologicals, are expected to eventually supplant chemical pesticides and fertilizers. According to analysts at DataHorizzon Research, the biologicals sector is forecasted to grow at a CAGR of 13.3%, reaching a market size of US$45.3 billion by 2032.

BVT recently updated its corporate partnership strategy, securing new international trials and expanding the use of its flagship asset, CR-7. The company also announced the results from a Michigan State University trial, demonstrating that CR-7 effectively reduces early disease infection and fungal disease by over 90% compared to untreated plots, matching the efficacy of conventional chemical treatments.

“We can confidently conclude from the Michigan State University trial that BVT’s CR-7 controls fungal disease extremely well as a spray application,” said Dr. Mason Newark, Field Technical Manager at BVT. “This trial demonstrates that CR-7 could be integrated into a pre-bloom or post-bloom spray program to extend disease control throughout the season.”

Over the past year, BVT has already achieved significant milestones with trial announcements in Spain with Agrobío, Mexico with a major multinational grower, and South Africa with MBFi, highlighting the expanded use of the proprietary plant-beneficial microbe, Clonostachys rosea CR-7, as a foliar application. This expansion included the product’s first sale to BioSafe Systems. Building on the successful Michigan State University trial results, plans are in place to repeat these trials in the coming years. To further bolster its technical and strategic capabilities, the company has welcomed seed and crop protection veteran Gustavo C. Gonzalez to its Board of Directors.

“Gustavo’s appointment is a reflection of our commitment to lead the industry into a future where innovation and sustainability are at the core of growth,” said Ashish Malik, CEO of Bee Vectoring Technologies. “His extensive experience in agribusiness and profound understanding of the international market dynamics will be pivotal as we scale our unique technology. We are thrilled to harness his expertise as we continue to revolutionize the way crops are cultivated and protected.”

Working to make food production more sustainable, leading crop inputs and services provider Nutrien Ltd. (NYSE:NTR) (TSX: NTR) recently released its Global Sustainability Report, detailing the company’s performance and progress no its sustainability initiatives up until year-end 2023. Among the key highlights, Nutrien noted measured, documented and calculated sustainable outcomes on approximately two million sustainably engaged acres in North America, South America and Australia.

“Nutrien has a critical role to play in helping provide the food, fuel and fiber the world needs,” said Tim Faveri, Vice President, Sustainability and Stakeholder Relations for Nutrien. “In 2023, we continued to build strategic partnerships to help amplify our impact while refining our sustainability strategy to align with core business objectives that support both the environment and our people, customers, supply chain partners, communities and shareholders.”

Further demonstrating its commitment to shape future agriculture leaders, Nutrien subsidiary Nutrien Ag Solutions announced a multi-year commitment of nearly $850,000 to the National FFA Organization. As per the commitment, Nutrien will donate $282,500 per year to support a variety of National FFA Organization programs and events from 2024 through 2026.

According to Bruce Bodine, newly-appointed CEO of The Mosaic Company (NYSE: MOS), fertilizer demand is set to rise. Mosaic is coming off of recently hosting members of the agriculture community in Florida to tour their phosphate operations, and learn more about the company’s Advanced Crop Nutrition (ACN) program. The ACN program is supported by Mosaic Biosciences’ BioPath and PowerCoat products, which are both biological fertilizer components formulated with proven strains of Plant Growth Promoting Rhizobacteria (PGPR), that increase nutrient availability, uptake, and utilization.

“At Mosaic, we view soil health as a system approach, therefore any change to one part of the system affects other parts,” said Keith Byerly, Commercial Sustainability Lead, for The Mosaic Company in an interview with CropLife. “For example, if you cut out seed treatments, the microbial, or the soil fertility program, you’re unlikely to achieve optimum soil health. In addition, you’ve disrupted the balance and equilibrium of the system.”

The world’s largest ammonia producer CF Industries Holdings, Inc. (NYSE: CF) recently announced the execution of a joint development agreement (JDA) with Japan’s largest energy company JERA Co. Inc. (JERA), to explore the development of greenfield low-carbon ammonia production capacity at CF Industries’ Blue Point Complex in Louisiana. As per the JDA, CF Industries and JERA will evaluate a joint venture agreement to build an approximately 1.4 million metric ton capacity low-carbon ammonia plant, with JERA contemplating a 48% ownership stake in the project, as well as a potential offtake agreement to procure more than 500,000 metric tons of low-carbon ammonia annually to meet demand for low-carbon fuels in Japan.

“We are pleased to expand our relationship with JERA as our companies advance leading-edge decarbonization initiatives that will help JERA and Japan achieve their decarbonization goals,” said Tony Will, President and CEO of CF Industries Holdings, Inc. “We believe that JERA’s projects, which represent the first meaningful volume of what we believe will be substantial global demand for low-carbon ammonia as an energy source, will demonstrate the significant contribution ammonia can make to meet the decarbonization goals of hard-to-abate industries.”

Upon the potential closing of somewhat controversial merger between Bunge Global SA (NYSE: BG) and Viterra, the duo have already named the executive leadership team for the combined company that would be solidified as the world’s largest oilseed processor, which would be led by Bunge’s current CEO, Greg Heckman.

“The future combined company will expand its reach into more crops and countries, offering farmers greater market access and differentiated, value-added solutions in all key origins,” said Heckman. “Food, feed & fuel customers will benefit from a broader product portfolio and expanded global supply options.”

Bunge is also coming off of an approved final investment decision with Chevron to build a new oilseed processing plant adjacent to its existing processing facility located on the Gulf Coast in Lousiana. Operated under the jointly owned Bunge Chevron Ag Renewables LLC, the plant features a flexible design, intended to process soybeans as well as softseeds, including novel winter oilseed crops, such as winter canola and CoverCress, among others.

Article Source: https://usanewsgroup.com/2024/04/26/the-currency-of-tomorrow-why-investing-in-cutting-edge-ai-recognition-tech-could-mean-big-money/ 

USA News Group
Editorial Staff
CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Bee Vectoring Technologies International Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Bee Vectoring Technologies International Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Bee Vectoring Technologies International Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares Bee Vectoring Technologies International Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Bee Vectoring Technologies International Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/climate-smart-commodities-program-to-benefit-180-000-farms-agritech-leads-the-way-302141522.html